Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2011

01.12.2011 | Research Article

The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Background Although, guidelines for the appropriate use of enoxaparin are published, yet the extent of their implementation in clinical practice is still questionable. Furthermore, the optimal dosing of enoxaparin in special populations such as renal insufficiency and obesity remains controversial. In the Middle East, there are insufficient data on the appropriateness of enoxaparin use in different indications. Objective (1) To assess the appropriateness of enoxaparin dosing and duration per indication in compliance with the recommended guidelines and their impact on safety and efficacy outcomes in Lebanese health care centers. (2) To evaluate the influence of the hospital type (teaching vs. non-teaching) on the extent of compliance with established guidelines. Setting Seventeen health care centers in Lebanon, including teaching and non-teaching hospitals. Methods An observational, cross-sectional, multicenter study was conducted in 17 Lebanese hospitals. Data on demographics, indication, dosing regimen and clinical outcomes were collected. The appropriateness of dosing practices was determined as per the ACCP guidelines and the FDA dosing recommendations. Main outcome measure The appropriateness of enoxaparin dosing was compared across different hospital type and among special populations including severe renal insufficiency and very obese patients. Results Of the 463 patients who participated in the study, 40% received improper enoxaparin dosing, which was mostly observed in the VTE prophylaxis group (41.6%, P < 0.001). When comparing the overall dosing practices in Lebanese hospitals, there was no statistically significant difference in the correctness of enoxaparin dosing between teaching and non-teaching hospitals (61.6% vs. 58.2%, P = 0.449), respectively. Only 11.5% of renally impaired patients and 59.4% of obese patients received correct doses. Conclusion This study highlighted the improper practice and thus the need of implementation of clinical practice guidelines for the dosing of enoxaparin, in Lebanese hospitals.
Literatur
1.
Zurück zum Zitat Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337(7):447–52.PubMedCrossRef Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337(7):447–52.PubMedCrossRef
2.
Zurück zum Zitat Blazing M, de Lemos J, White H, Fox K, Verheugt F, Ardissino D, et al. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial. JAMA. 2004;292(10):55–64.PubMedCrossRef Blazing M, de Lemos J, White H, Fox K, Verheugt F, Ardissino D, et al. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial. JAMA. 2004;292(10):55–64.PubMedCrossRef
3.
Zurück zum Zitat Ferguson J, Califf R, Antman E, Cohen M, Grines C, Goodman S, et al. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA. 2004;292(1):45–54.PubMedCrossRef Ferguson J, Califf R, Antman E, Cohen M, Grines C, Goodman S, et al. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA. 2004;292(1):45–54.PubMedCrossRef
4.
Zurück zum Zitat Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight-heparin compared with intravenous heparin for treatment of pulmonary embolism. Ann Intern Med. 2004;140(3):175–83.PubMed Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight-heparin compared with intravenous heparin for treatment of pulmonary embolism. Ann Intern Med. 2004;140(3):175–83.PubMed
5.
Zurück zum Zitat Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med. 2001;134(3):191–202.PubMed Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med. 2001;134(3):191–202.PubMed
6.
Zurück zum Zitat Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res. 2000;100(2):V113–20.PubMedCrossRef Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res. 2000;100(2):V113–20.PubMedCrossRef
7.
Zurück zum Zitat Hirsh J, Warkentin T, Raschke R, Granger C, Ohman E, Dalen J. Heparin and low-molecular-weight heparin. Chest. 1999;115(6):489–510. Hirsh J, Warkentin T, Raschke R, Granger C, Ohman E, Dalen J. Heparin and low-molecular-weight heparin. Chest. 1999;115(6):489–510.
8.
Zurück zum Zitat Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(21):688–98.PubMed Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(21):688–98.PubMed
9.
Zurück zum Zitat Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):141S–59S.PubMedCrossRef Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):141S–59S.PubMedCrossRef
10.
Zurück zum Zitat Geerts W, Bergqvist D, Pineo G, Heit J, Samama C, Lassen M, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):381S–453S.PubMedCrossRef Geerts W, Bergqvist D, Pineo G, Heit J, Samama C, Lassen M, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):381S–453S.PubMedCrossRef
11.
Zurück zum Zitat Kearon C, Kahn S, Agnelli G, Goldhaber S, Raskob G, Comerota A. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):454S–545S.PubMedCrossRef Kearon C, Kahn S, Agnelli G, Goldhaber S, Raskob G, Comerota A. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):454S–545S.PubMedCrossRef
12.
Zurück zum Zitat Harrington R, Becker R, Cannon C, Gutterman D, Lincoff A, Popma J, et al. Antithrombotic therapy for non ST segment elevation acute coronary syndromes: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):670S–707S.PubMedCrossRef Harrington R, Becker R, Cannon C, Gutterman D, Lincoff A, Popma J, et al. Antithrombotic therapy for non ST segment elevation acute coronary syndromes: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):670S–707S.PubMedCrossRef
13.
Zurück zum Zitat Sanofi-Aventis US LLC. Lovenox® (enoxaparin sodium injection) prescribing information. Bridgewater: Sanofi-Aventis US LLC; 2008. Sanofi-Aventis US LLC. Lovenox® (enoxaparin sodium injection) prescribing information. Bridgewater: Sanofi-Aventis US LLC; 2008.
14.
Zurück zum Zitat Chopard P, Dörffler-Melly J, Hess U, Wuillemin W, Hayoz D, Gallino A, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005;257(4):352–7.PubMedCrossRef Chopard P, Dörffler-Melly J, Hess U, Wuillemin W, Hayoz D, Gallino A, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005;257(4):352–7.PubMedCrossRef
15.
Zurück zum Zitat Becker R, Spencer F, Gibson M, Rush J, Sanderink G, Murphy S, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST elevation acute coronary syndromes. Am Heart J. 2002;143(5):753–9.PubMedCrossRef Becker R, Spencer F, Gibson M, Rush J, Sanderink G, Murphy S, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST elevation acute coronary syndromes. Am Heart J. 2002;143(5):753–9.PubMedCrossRef
16.
Zurück zum Zitat Mahe I, Gouin-Thibalt I, Drouet L, Simoneau G, Di Castillo H, Siguret V, et al. Elderly medical patients created with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging. 2007;24:63–71.PubMedCrossRef Mahe I, Gouin-Thibalt I, Drouet L, Simoneau G, Di Castillo H, Siguret V, et al. Elderly medical patients created with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging. 2007;24:63–71.PubMedCrossRef
17.
Zurück zum Zitat Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673–84.PubMed Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673–84.PubMed
18.
Zurück zum Zitat Montalescot G, Collet J, Tanguy M, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110(4):392–8.PubMedCrossRef Montalescot G, Collet J, Tanguy M, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110(4):392–8.PubMedCrossRef
19.
Zurück zum Zitat Turpie A. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (medenox) Trial. Am J Cardiol. 2000;86:48–52.CrossRef Turpie A. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (medenox) Trial. Am J Cardiol. 2000;86:48–52.CrossRef
20.
Zurück zum Zitat Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31.PubMedCrossRef Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31.PubMedCrossRef
21.
Zurück zum Zitat Sanderink G, Le Liboux A, Jariwala N, Harding N, Ozoux M, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–18.PubMedCrossRef Sanderink G, Le Liboux A, Jariwala N, Harding N, Ozoux M, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–18.PubMedCrossRef
22.
Zurück zum Zitat Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41–50.PubMedCrossRef Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41–50.PubMedCrossRef
23.
Zurück zum Zitat Wilson S, Wilbur K, Burton E, Anderson D. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42–8.PubMed Wilson S, Wilbur K, Burton E, Anderson D. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42–8.PubMed
24.
Zurück zum Zitat Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular weight heparins in special populations. Pharmacotherapy. 2001;21(2):218–34.PubMedCrossRef Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular weight heparins in special populations. Pharmacotherapy. 2001;21(2):218–34.PubMedCrossRef
25.
Zurück zum Zitat Kucher N, Leizorovicz A, Vaitkus P, Cohen A, Turpie A, Olsson C, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165(3):341–5.PubMedCrossRef Kucher N, Leizorovicz A, Vaitkus P, Cohen A, Turpie A, Olsson C, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165(3):341–5.PubMedCrossRef
26.
Zurück zum Zitat Rondina M, Wheeler M, Rodgers G, Draper L, Pendleton R. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res. 2010;125(3):220–3.PubMedCrossRef Rondina M, Wheeler M, Rodgers G, Draper L, Pendleton R. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res. 2010;125(3):220–3.PubMedCrossRef
27.
Zurück zum Zitat Vats V, Nutescu E, Theobald J, Wojtynek J, Schumock G. Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm. 2007;64(11):1203–8.PubMedCrossRef Vats V, Nutescu E, Theobald J, Wojtynek J, Schumock G. Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm. 2007;64(11):1203–8.PubMedCrossRef
28.
Zurück zum Zitat World Health Organization. Report of a WHO consultation on obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 1998. World Health Organization. Report of a WHO consultation on obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 1998.
29.
Zurück zum Zitat Cockcroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef Cockcroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef
30.
Zurück zum Zitat Macie C, Forbes L, Foster G, Douketis J. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004;125(5):1616–21.PubMedCrossRef Macie C, Forbes L, Foster G, Douketis J. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004;125(5):1616–21.PubMedCrossRef
31.
Zurück zum Zitat Al-Sallami H, Jordan S, Ferguson R, Medlicott N, Schollum J, Duffull S. Current enoxaparin dosing guidelines have dubious credibility. N Z Med J. 2010;123(1313):62–7.PubMed Al-Sallami H, Jordan S, Ferguson R, Medlicott N, Schollum J, Duffull S. Current enoxaparin dosing guidelines have dubious credibility. N Z Med J. 2010;123(1313):62–7.PubMed
32.
Zurück zum Zitat Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. J Thromb Thrombolysis. 2011;31(1):47–56.PubMedCrossRef Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. J Thromb Thrombolysis. 2011;31(1):47–56.PubMedCrossRef
33.
Zurück zum Zitat Rothberg M, Lahti M, Pekow P, Lindenauer P. Venous thromboembolism prophylaxis among medical patients at US hospitals. J Gen Intern Med. 2010;25(6):489–94.PubMedCrossRef Rothberg M, Lahti M, Pekow P, Lindenauer P. Venous thromboembolism prophylaxis among medical patients at US hospitals. J Gen Intern Med. 2010;25(6):489–94.PubMedCrossRef
34.
Zurück zum Zitat Masroujeh R, Shamseddeen W, Isma’eel H, Otrock Z, Khalil I, Taher A, et al. Underutilization of venous thromboembolism prophylaxis in medical patients in a tertiary care center. J Thromb Thrombolysis. 2008;26(2):138–41.PubMedCrossRef Masroujeh R, Shamseddeen W, Isma’eel H, Otrock Z, Khalil I, Taher A, et al. Underutilization of venous thromboembolism prophylaxis in medical patients in a tertiary care center. J Thromb Thrombolysis. 2008;26(2):138–41.PubMedCrossRef
35.
Zurück zum Zitat Tincani E, Crowther M, Turrini F, Prisco D. Prevention and treatment of venous thromboembolism in the elderly population. Clin Interv Aging. 2007;2(2):237–46.PubMed Tincani E, Crowther M, Turrini F, Prisco D. Prevention and treatment of venous thromboembolism in the elderly population. Clin Interv Aging. 2007;2(2):237–46.PubMed
36.
Zurück zum Zitat Spicer K, Gibson P, Bloe C, Cross S, Leslie S, et al. Weight assessment in cardiac patients: implications for prescription of low molecular weight heparin. Postgrad Med J. 2009;85(1001):124–7.PubMedCrossRef Spicer K, Gibson P, Bloe C, Cross S, Leslie S, et al. Weight assessment in cardiac patients: implications for prescription of low molecular weight heparin. Postgrad Med J. 2009;85(1001):124–7.PubMedCrossRef
37.
Zurück zum Zitat Scholten D, Hoedema R, Scholten S. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19–24.PubMedCrossRef Scholten D, Hoedema R, Scholten S. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19–24.PubMedCrossRef
38.
Zurück zum Zitat Ellis M, Hadari R, Tchuvrero N, Shapira S, Kovlenko I, Kozmiakova M, et al. Hemorrhagic complications in patients treated with anticoagulant doses of low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost. 2006;12(2):199–204.PubMedCrossRef Ellis M, Hadari R, Tchuvrero N, Shapira S, Kovlenko I, Kozmiakova M, et al. Hemorrhagic complications in patients treated with anticoagulant doses of low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost. 2006;12(2):199–204.PubMedCrossRef
39.
Zurück zum Zitat Nieto J, Solano R, Ruiz-Ribo M, Ruiz-Gimenez N, Prandoni P, Kearon C, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. Thromb Haemostasis. 2010;8(6):1216–22.CrossRef Nieto J, Solano R, Ruiz-Ribo M, Ruiz-Gimenez N, Prandoni P, Kearon C, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. Thromb Haemostasis. 2010;8(6):1216–22.CrossRef
40.
Zurück zum Zitat The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMT 11A. J Am Coll Cardiol. 1997;29(7):1474–82.CrossRef The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMT 11A. J Am Coll Cardiol. 1997;29(7):1474–82.CrossRef
41.
Zurück zum Zitat Gouin-Thibalt I, Pautas E, Siguret V. Safety profiles of different low molecular weight heparins used at therapeutic dose. Drug Saf. 2005;28(4):333–49.CrossRef Gouin-Thibalt I, Pautas E, Siguret V. Safety profiles of different low molecular weight heparins used at therapeutic dose. Drug Saf. 2005;28(4):333–49.CrossRef
42.
Zurück zum Zitat Al-Sallami H, Barras M, Green B, Duffull S. Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet. 2010;49(9):567–71.PubMedCrossRef Al-Sallami H, Barras M, Green B, Duffull S. Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet. 2010;49(9):567–71.PubMedCrossRef
Metadaten
Titel
The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study
Publikationsdatum
01.12.2011
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2011
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-011-9559-1

Weitere Artikel der Ausgabe 6/2011

International Journal of Clinical Pharmacy 6/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.